Document Classification

Section Type: RESULTS

Text: For UNCOVER-2 and UNCOVER-3 respectively, in the ixekizumab every 2 weeks group, PASI 75 was achieved by 315 (response rate 897 % ; [effect size 874 % (975 % CI 829-918) vs placebo ; 481 % (412-550) vs etanercept]) and 336 (873 % ; [800 % (744-857) vs placebo ; 339 % (270-407) vs etanercept]) patients ; in the ixekizumab every 4 weeks group, by 269 (775 % ; [751 % (695-808) vs placebo ; 359 % (282-436) vs etanercept]) and 325 (842 % ; [769 % (710-828) vs placebo ; 308 % (237-379) vs etanercept]) patients ; in the placebo group, by four (24 %) and 14 (73 %) patients ; and in the etanercept group by 149 (416 %) and 204 (534 %) patients (all p < 00001 vs placebo or etanercept).